Theradaptive’s Chief Scientific Officer Frank Vizesi provides an overview of the company’s unique protein and how it hopes to disrupt the bone replacement market in an interview with SmartTRAK at the 2025 NASS Biologic Interventions Meeting.
Frank Vizesi, chief scientific officer of Theradaptive, discusses how the company is focused on creating a new recombinant BMP-2 to solve existing problems within the Bone Replacement Market in an interview with SmartTRAK on May 9, 2025, at the 2025 North American Spine Society (NASS) Biologics Interventions meeting in Chicago, Illinois. The company is developing a new version of recombinant BMP-2 called AMP-2, an adhesive variant of BMP-2 that retains the whole protein structure of BMP-2 and all its potency to bind to implant surfaces tightly.
Click on the following video (10:47 min) to learn more. A link to download a complete transcript of the interview is also provided below.
SmartTRAK: Hi, this is Erin Dorgan, senior analyst here at SmartTRAK. I'm here today with Frank Vizesi, chief scientific officer at Theradaptive. Thank you so much. I appreciate your time. Do you mind sharing a little more about your background and role at Theradaptive?
Frank Vizesi: Sure. Thanks for having me today. So my background, originally PhD, biomedical engineer from Sydney, Australia. Was very lucky to do my studies with the great professor, Bill Walsh, a good friend, and we still talk almost daily at this point.
My background now, I've been in the spine industry based out of San Diego, California for almost 20 years. Started off with NuVasive in the biologics R&D team there. I then left to join a spin out called SeaSpine. Ultimately I was the chief scientific officer of SeaSpine. Then we were acquired and merged with Orthofix and I became the chief scientific officer of the combined company then.
About a year ago, just a little over a year ago, I left to join a new startup called Theradaptive, the company who I've been tracking for probably about five or six years. Being in the biologic space I'm always interested to find out where the next most advanced bone graft is going to come from. I've been tracking quite a few different companies and I just sort of fell in love with the technology of Theradaptive, it's very advanced, and the team there. And decided that the best way to help bring your really advanced bone biologic product to market that can really help patients and solve problems would be to come and join the company.
It was the first time for me to join a startup, my previous background all being in publicly traded companies, but I've been having a blast.
Can you share a little bit more about the technology at Theradaptive and what they're doing?
FV: Yeah, sure. So let me start first with maybe the opportunity or the problem. So right now in the biologic space, surgeons really have a choice between ...
Want to learn more about Theradaptive and how it hopes to disrupt the bone replacement market? Click the button below to download and read the complete transcript of our exclusive interview with Frank Vizesi, CSO of Theradaptive, conducted by Erin Dorgan, SmartTRAK Sr Analyst, Spine & Bone Replacement.
SmartTRAK is the Medtech industry’s only global Insights-as-a-Service solution for the Orthopedics, Wound Care, Regenerative Medicine and Neuro Therapy markets. SmartTRAK’s proprietary methodology turns disparate data from hundreds of sources into powerful insights customers can rely on as the trusted source for strategic decision-making. The SmartTRAK enterprise platform includes rich daily updates, comprehensive market coverage and simple-to-use tools and dashboards for market, product and financial analysis. Customers leveraging the SmartTRAK platform also have direct access to market experts for inquiries and advisory services. If you would like a demo of what SmartTRAK has to offer and see how we can help increase proficiency, improve productivity and reduce costs for your company, just click here.
